All In Biotech

Drug Trial Radar · NCT07143331

A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of KS101 in Healthy Volunteers, Including a Pilot Food Effect Evaluation

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Aug 30, 2025

Primary completion

Apr 1, 2026

Study completion Aug 6, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is the first clinical trial involving study drug KS101. The goal of this clinical trial is to investigate whether KS101 is safe, whether it causes side effects, and how KS101 is broken down in the body, in healthy participants. This information will be used to learn more about KS101 and to determine the most effective dose for age related diseases such as chronic kidney disease and Alzheimer's Disease, with the fewest unwanted side effects. There are 3 parts to this study. In Part 1, participants will take KS101 or a placebo once and will stay in the study centre for a 4-night inpatient stay. Participants will return for outpatient visits on Days 8 and 29. In Part 2, participants will take KS101 twice, once after a meal and once without a meal and will stay in the study centre for a 7-night inpatient stay. Participants will return for outpatient visits on Days 11 and 32. In Part 3, participants will take KS101 or a placebo once daily for 5 days and will stay in the study centre for an 8-night inpatient stay. Participants will return for outpatient visits on Days 12 and 33.

Conditions

  • Healthy Participants
  • Alzheimer Disease
  • Chronic Kidney Disease

Interventions

  • Part 1 KS101Drug

    Six doses of oral KS101 will be administered to participants.

  • Part 1 PlaceboDrug

    Six doses of oral matching placebo will be administered to participants.

  • Part 2 with FoodDrug

    KS101 administered with food

  • Part 2 without foodDrug

    KS101 administered without food

  • Part 3 KS101Drug

    3 multiple doses of KS101

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of single and multiple ascending oral doses of KS101 in healthy adult volunteers.Time frame: Through to end of study, up to 63 days.
  2. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes observed during the physical examination.Time frame: Through to end of study, up to 63 days.
  3. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in haematology parameters.Time frame: Through to end of study, up to 63 days.
  4. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in serum biochemistry.Time frame: Through to end of study, up to 63 days.
  5. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in coagulation parameters.Time frame: Through to end of study, up to 63 days.
  6. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in urinalysis parameters.Time frame: Through to end of study, up to 63 days.
  7. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in vital signs.Time frame: Through to end of study, up to 63 days.
  8. Evaluation of the safety and tolerability of a single oral dose of KS101 taken after a high-fat meal, assessed by changes in ECG parameters.Time frame: Through to end of study, up to 63 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Sydney, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.